| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma
|
Marr, K.C.
|
|
|
28 |
4 |
p. 849-854
|
artikel
|
| 2 |
Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry?
|
Font, R.
|
|
|
28 |
4 |
p. 831-835
|
artikel
|
| 3 |
Adjuvant FOLFOX +/− cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients
|
Taieb, J.
|
|
|
28 |
4 |
p. 824-830
|
artikel
|
| 4 |
Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials
|
Gyawali, B.
|
|
|
28 |
4 |
p. 898-899
|
artikel
|
| 5 |
Adjuvant sunitinib in renal cell carcinoma: from evidence to recommendation
|
Bex, A.
|
|
|
28 |
4 |
p. 682-684
|
artikel
|
| 6 |
A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder
|
Obara, W.
|
|
|
28 |
4 |
p. 798-803
|
artikel
|
| 7 |
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma
|
Jonasch, E.
|
|
|
28 |
4 |
p. 804-808
|
artikel
|
| 8 |
Association of plasma concentrations of branched-chain amino acids with risk of colorectal adenoma in a large Japanese population
|
Budhathoki, S.
|
|
|
28 |
4 |
p. 818-823
|
artikel
|
| 9 |
Cancer vaccines at the age of immune checkpoint inhibitors: reasonable approach as combination therapy in advanced urothelial carcinoma?
|
Grivas, P.
|
|
|
28 |
4 |
p. 680-682
|
artikel
|
| 10 |
Chemotherapy in end-of-life care
|
Heikkilä, R.
|
|
|
28 |
4 |
p. 684-685
|
artikel
|
| 11 |
Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group
|
Tchernonog, E.
|
|
|
28 |
4 |
p. 843-848
|
artikel
|
| 12 |
Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma
|
Lee, J.-K.
|
|
|
28 |
4 |
p. 890-897
|
artikel
|
| 13 |
Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies
|
Tang, H.
|
|
|
28 |
4 |
p. 733-740
|
artikel
|
| 14 |
Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequentBAP1,PIK3CA, and other actionable genomic alterations
|
Wang, K.
|
|
|
28 |
4 |
p. 748-753
|
artikel
|
| 15 |
Consideration of an association between performance status and ramucirumab efficacy
|
Yoon, H.H.
|
|
|
28 |
4 |
p. 902-903
|
artikel
|
| 16 |
Detecting mutant KRAS in liquid biopsies: a biomarker searching for a role
|
Szallasi, Z.
|
|
|
28 |
4 |
p. 677-678
|
artikel
|
| 17 |
Differential protein stability and clinical responses ofEML4-ALK fusion variants to various ALK inhibitors in advancedALK-rearranged non-small cell lung cancer
|
Woo, C.G.
|
|
|
28 |
4 |
p. 791-797
|
artikel
|
| 18 |
Editorial board
|
|
|
|
28 |
4 |
p. ii-iii
|
artikel
|
| 19 |
Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial
|
Liang, J.
|
|
|
28 |
4 |
p. 777-783
|
artikel
|
| 20 |
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
|
McGee, J.
|
|
|
28 |
4 |
p. 702-710
|
artikel
|
| 21 |
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions
|
Karam, A.
|
|
|
28 |
4 |
p. 711-717
|
artikel
|
| 22 |
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours
|
Leary, A.F.
|
|
|
28 |
4 |
p. 718-726
|
artikel
|
| 23 |
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
|
Wilson, M.K.
|
|
|
28 |
4 |
p. 727-732
|
artikel
|
| 24 |
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
|
Bell, R.
|
|
|
28 |
4 |
p. 754-760
|
artikel
|
| 25 |
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
|
Bang, Y.J.
|
|
|
28 |
4 |
p. 855-861
|
artikel
|
| 26 |
High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients
|
Allenson, K.
|
|
|
28 |
4 |
p. 741-747
|
artikel
|
| 27 |
Immune checkpoint inhibitors-related orchitis
|
Brunet-Possenti, F.
|
|
|
28 |
4 |
p. 906-907
|
artikel
|
| 28 |
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
|
Swain, S.M.
|
|
|
28 |
4 |
p. 761-768
|
artikel
|
| 29 |
Mildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment
|
Wymer, K.M.
|
|
|
28 |
4 |
p. 899-902
|
artikel
|
| 30 |
More valuable than platinum: first-line pembrolizumab in advanced stage non-small-cell lung cancer
|
Zou, T.
|
|
|
28 |
4 |
p. 685-687
|
artikel
|
| 31 |
Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer
|
M-Rabet, M.
|
|
|
28 |
4 |
p. 769-776
|
artikel
|
| 32 |
No pain, no gain… What we can learn from a trial reporting negative results
|
Di Leo, A.
|
|
|
28 |
4 |
p. 678-680
|
artikel
|
| 33 |
Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA
|
Remon, J.
|
|
|
28 |
4 |
p. 784-790
|
artikel
|
| 34 |
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer
|
Tsao, M.-S.
|
|
|
28 |
4 |
p. 882-889
|
artikel
|
| 35 |
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
|
Hui, R.
|
|
|
28 |
4 |
p. 874-881
|
artikel
|
| 36 |
Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)
|
Rummel, M.
|
|
|
28 |
4 |
p. 836-842
|
artikel
|
| 37 |
Reply to the letter to the editor ‘Integrating communication as a core skill in the global curriculum for medical oncology’ by Horlait et al.
|
Dittrich, C.
|
|
|
28 |
4 |
p. 905-906
|
artikel
|
| 38 |
Reply to the Letter to the editor ‘Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial’ by Fornaro et al.
|
Ikeda, M.
|
|
|
28 |
4 |
p. 903-904
|
artikel
|
| 39 |
Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience
|
Meerveld-Eggink, A.
|
|
|
28 |
4 |
p. 862-867
|
artikel
|
| 40 |
Statistical controversies in clinical research: comparison of primary outcomes in protocols, public clinical-trial registries and publications: the example of oncology trials
|
Perlmutter, A.S.
|
|
|
28 |
4 |
p. 688-695
|
artikel
|
| 41 |
Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies
|
Wages, N.A.
|
|
|
28 |
4 |
p. 696-701
|
artikel
|
| 42 |
Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation
|
Schrader, J.
|
|
|
28 |
4 |
p. 904-905
|
artikel
|
| 43 |
Table of Contents
|
|
|
|
28 |
4 |
p. iv-vii
|
artikel
|
| 44 |
The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients
|
Lian, B.
|
|
|
28 |
4 |
p. 868-873
|
artikel
|
| 45 |
Use of chemotherapy near the end of life: what factors matter?
|
Rochigneux, P.
|
|
|
28 |
4 |
p. 809-817
|
artikel
|
Tijdschrift beschrijving